Genexine, Inc. | MedPath

Pipeline Analysis Reveals 75+ Drug Candidates in Development for Advanced Cervical Cancer Treatment

4 months ago

• DelveInsight's comprehensive analysis identifies over 70 pharmaceutical companies actively developing 75+ pipeline drugs for advanced cervical cancer treatment. • AstraZeneca's Imfinzi (durvalumab) leads late-stage developments, currently in Phase III trials for locally advanced cervical cancer, building on its success in lung cancer treatment. • Key clinical trials include promising immunotherapy combinations, with Merck's pembrolizumab plus chemoradiotherapy and AstraZeneca's volrustomig studies scheduled for significant developments in 2025.